FOLD logo

Amicus Therapeutics (FOLD) Company Overview

Profile

Full Name:

Amicus Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 31, 2007

Indexes:

Not included

Website:

http://amicusrx.com

Description:

Amicus Therapeutics, Inc. is a global biotechnology company dedicated to the discovery, development, and delivery of medicines for the treatment of rare diseases. Amicus Therapeutics, Inc. was registered in 2002, with its headquarters located in Philadelphia, Pennsylvania. The company's main product is Galafold, the first approved oral precision medicine for people living with Fabry disease and having genetically amenable variants. The drug is approved under the trade name Galafold in the United States, European Union, United Kingdom, and Japan, with several additional approvals and applications under review in multiple regions worldwide.

Key Details

Price

$9.35

Market Cap

$2.87 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$528.29 M(+32.29% YoY)

Annual EPS

-$0.18(+64.71% YoY)

PE Ratio

-

Annual ROE

-31.68%

Annual Debt To Equity

2.01

Beta

0.87

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Feb 19, 2025

Recent annual earnings:

Feb 19, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 20, 25 Wells Fargo
Overweight
Feb 20, 25 Needham
Hold
Jan 15, 25 Cantor Fitzgerald
Overweight
Jan 13, 25 Needham
Hold
Dec 13, 24 Morgan Stanley
Equal-Weight
Nov 12, 24 JP Morgan
Overweight
Nov 7, 24 UBS
Buy
Nov 7, 24 Needham
Hold
Nov 7, 24 Guggenheim
Buy
Nov 7, 24 Cantor Fitzgerald
Overweight

Screeners with FOLD included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks below SMA 200
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
Best performing stocks last 15 years
Biotechnology industry

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$9.35
FOLD price is $9.35

Price All-time High

$24.89
FOLD price is currently -62.45% below its historical high of $24.89

Price Analysts Target

$17.00
FOLD price is currently -45.03% lower than the consensus analysts' forecast

Price Today Change

-4.25%
FOLD price is down -4.25% today

Price YTD Change

-0.8%
FOLD price is down -0.8% since January 1st

Price 3-Year Change

+16.23%
FOLD price is up +16.23% over the past 3 years

Market cap

Market Cap

$2.87 B
FOLD market capitalization is $2.87 billion

Market Cap 3-Year Change

+27.52%
FOLD market capitalization is up +27.52% over the past 3 years

Market Cap All-time High

$6.49 B
FOLD market capitalization is currently -55.73% below its historical high of $6.49 billion

Market Cap Sector Rank

84.87%
FOLD market capitalization is higher than 84.87% of companies in Healthcare sector

Technical

Beta

0.87
FOLD beta is 0.87

200-day SMA

$10.29
FOLD price is currently -9.18% below its 200-day simple moving average

14-day RSI

50.65
FOLD 14-day relative strength index is 50.65

30-day Relative Volume

0.92
FOLD 30-day relative volume is 0.92

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$528.29 M
FOLD annual revenue is $528.29 million

Annual Revenue Analysts Estimate

$631.41 M
FOLD annual revenue is currently -16.33% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+32.29%
FOLD annual revenue is up +32.29% year-on-year

Annual Revenue Sector Rank

75%
FOLD annual revenue is higher than 75% of companies in Healthcare sector

Profit

Annual Gross Profit

$475.35 M
FOLD annual gross profit is $475.35 million

Annual Gross Margin

89.98%
FOLD annual gross profit margin is 89.98%

Annual Operating Profit

$34.06 M
FOLD annual operating income is $34.06 million

Annual Operating Margin

6.45%
FOLD annual operating profit margin is 6.45%

Annual Net Income

-$56.11 M
FOLD annual net profit is -$56.11 million

Annual Net Margin

-10.62%
FOLD annual net profit margin is -10.62%

EPS

Annual EPS

-$0.18
FOLD annual earnings per share is -$0.18

Annual EPS Analysts Estimate

$0.44
FOLD annual earnings per share is currently -141.14% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+64.71%
FOLD annual earnings per share is up +64.71% year-on-year

Annual EPS Sector Rank

78.27%
FOLD annual earnings per share is higher than 78.27% of companies in Healthcare sector

ROA & ROE

Annual ROA

-7.18%
FOLD annual return on assets is -7.18%

Annual ROE

-31.68%
FOLD annual return on equity is -31.68%

EBIT & EBITDA

Annual EBIT

$20.84 M
FOLD annual earnings before interest & taxes is $20.84 million

Annual EBITDA

$29.39 M
FOLD annual EBITDA is $29.39 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
FOLD price to earnings ratio value is unknown

PE Ratio Sector Rank

-
FOLD price to earnings ratio is unknown

PB Ratio

PB Ratio

14.80
FOLD price to book ratio is 14.80

PB Ratio Sector Rank

94.31%
FOLD price to book ratio is higher than 94.31% of companies in Healthcare sector

PS Ratio

PS Ratio

5.43
FOLD price to sales ratio is 5.43

PS Ratio Sector Rank

64.84%
FOLD price to sales ratio is higher than 64.84% of companies in Healthcare sector

Enterprise value

Enterprise Value

$3.10 B
FOLD enterprise value is $3.10 billion

Enterprise Value Sector Rank

84.93%
FOLD enterprise value is higher than 84.93% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

105.52
FOLD EV/EBITDA is 105.52

EV/EBITDA Sector Rank

98.59%
FOLD EV/EBITDA is higher than 98.59% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

3.39
FOLD annual current ratio is 3.39

Annual Quick Ratio

2.60
FOLD annual quick ratio is 2.60

Leverage

Annual Debt To Equity

2.01
FOLD annual debt to equity ratio is 2.01

Annual Interest Coverage Ratio

0.42
FOLD annual interest coverage ratio is 0.42

Risk & Stability

Piotroski F-Score

4
FOLD piotroski f-score is 4

Altman Z-Score

-0.67
FOLD altman z-score is -0.67

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$785.03 M
FOLD annual total assets is $785.03 million

Annual Non Current Assets

$280.30 M
FOLD annual long term assets is $280.30 million

Annual Current Assets

$504.74 M
FOLD annual total current assets is $504.74 million

Annual Cash & Cash Equivalents

$213.75 M
FOLD annual cash & cash equivalents is $213.75 million

Equity

Annual Book Value

$194.04 M
FOLD annual book value is $194.04 million

Annual Working Capital

$356.03 M
FOLD annual working capital is $356.03 million

Liabilities

Annual Total Liabilities

$590.99 M
FOLD annual total liabilities is $590.99 million

Annual Total Long Term Liabilities

$442.29 M
FOLD annual total long term liabilities is $442.29 million

Annual Current Liabilities

$148.70 M
FOLD annual total current liabilities is $148.70 million

Annual Accounts Payable

$12.95 M
FOLD annual accounts payable is $12.95 million

Debt

Annual Total Debt

$443.64 M
FOLD annual total debt is $443.64 million

Annual Total Debt 1-Year Change

-0.32%
FOLD annual total debt is down -0.32% year-on-year

Annual Long Term Debt

$435.19 M
FOLD annual long term debt is $435.19 million

Annual Short Term Debt

$8.46 M
FOLD annual short term debt is $8.46 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$494.23 M
FOLD annual total expenses is $494.23 million

Annual Operating Expenses

$441.29 M
FOLD annual total operating expenses is $441.29 million

Annual Cost Of Goods Sold

$52.94 M
FOLD annual cost of goods sold is $52.94 million

Annual SGA

$323.38 M
FOLD annual SGA is $323.38 million

Annual D&A

$8.55 M
FOLD annual depreciation & amortization is $8.55 million

Annual Interest Expense

$49.60 M
FOLD annual interest expense is $49.60 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$33.89 M
FOLD annual cash flow from operations is -$33.89 million

Annual CFO 1-Year Change

+50.95%
FOLD annual cash flow from operations is up +50.95% year-on-year

Annual CFI

-$560.00 K
FOLD annual cash flow from investing activities is -$560.00 thousand

Annual CFI 1-Year Change

-100.57%
FOLD annual cash flow from investing activities is down -100.57% year-on-year

Annual CFF

$5.12 M
FOLD annual cash flow from financing activities is $5.12 million

Annual CFF 1-Year Change

-91.7%
FOLD annual cash flow from financing activities is down -91.7% year-on-year

Free CashFlow

Annual FCF

-$37.44 M
FOLD annual free cash flow is -$37.44 million

Annual FCF 1-Year Change

+51.07%
FOLD annual free cash flow is up +51.07% year-on-year

CAPEX

Annual CAPEX

$3.55 M
FOLD annual capital expenditures is $3.55 million

Annual CAPEX 1-Year Change

-52.24%
FOLD annual capital expenditures is down -52.24% year-on-year

Institutional Ownership

Similar stocks

LFST logo
LifeStance Health (LFST)
ALHC logo
Alignment Healthcare (ALHC)
AMED logo
Amedisys (AMED)
WRBY logo
Warby Parker (WRBY)
PRVA logo
Privia Health (PRVA)
APLS logo
Apellis Pharmaceuticals (APLS)
Concentra Group Holdings Parent (CON)
GeneDx Holdings (WGS)
XENE logo
Xenon Pharmaceuticals (XENE)

FAQ

  • What is the ticker symbol for Amicus Therapeutics?
  • Does Amicus Therapeutics pay dividends?
  • What sector is Amicus Therapeutics in?
  • What industry is Amicus Therapeutics in?
  • What country is Amicus Therapeutics based in?
  • When did Amicus Therapeutics go public?
  • Is Amicus Therapeutics in the S&P 500?
  • Is Amicus Therapeutics in the NASDAQ 100?
  • Is Amicus Therapeutics in the Dow Jones?
  • When was Amicus Therapeutics's last earnings report?
  • When does Amicus Therapeutics report earnings?
  • Should I buy Amicus Therapeutics stock now?

What is the ticker symbol for Amicus Therapeutics?

The ticker symbol for Amicus Therapeutics is NASDAQ:FOLD

Does Amicus Therapeutics pay dividends?

No, Amicus Therapeutics does not pay dividends

What sector is Amicus Therapeutics in?

Amicus Therapeutics is in the Healthcare sector

What industry is Amicus Therapeutics in?

Amicus Therapeutics is in the Biotechnology industry

What country is Amicus Therapeutics based in?

Amicus Therapeutics is headquartered in United States

When did Amicus Therapeutics go public?

Amicus Therapeutics's initial public offering (IPO) was on May 31, 2007

Is Amicus Therapeutics in the S&P 500?

No, Amicus Therapeutics is not included in the S&P 500 index

Is Amicus Therapeutics in the NASDAQ 100?

No, Amicus Therapeutics is not included in the NASDAQ 100 index

Is Amicus Therapeutics in the Dow Jones?

No, Amicus Therapeutics is not included in the Dow Jones index

When was Amicus Therapeutics's last earnings report?

Amicus Therapeutics's most recent earnings report was on Feb 19, 2025

When does Amicus Therapeutics report earnings?

The next expected earnings date for Amicus Therapeutics is May 9, 2025

Should I buy Amicus Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions